U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07714395) titled 'Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors' on June 19.

Brief Summary: This study is being done to test the safety of elraglusib when taken once a day and to assess:

* How the body processes the drug (pharmacokinetics)

* Assess potential effects of the drug on heart rhythm

* Find the highest daily dose that can be given without causing side effects

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Advanced Malignant Solid Tumor

Intervention: DRUG: Elraglusib Oral Tablets

Elraglusib Oral Tablet, 250 mg

Recruitment Status: NOT_YET_RECRUITING

Spon...